TY - JOUR
T1 - Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells
AU - Brennand, Kristen J.
AU - Landek-Salgado, Melissa A.
AU - Sawa, Akira
N1 - Funding Information:
This work was supported by U.S. Public Health Service Grants MH-10145401 (KJB), MH-084018 (AS), MH-094268 Silvo O. Conte Center (AS), MH-069853 (AS), MH-085226 (AS), MH-088753 (AS), and MH-092443 (AS); the Stanley (AS), RUSK (AS), and S&R Foundation (AS), National Alliance for Research on Schizophrenia and Depression (KJB, AS), and the Maryland Stem Cell Research Fund (AS).
PY - 2014/6/15
Y1 - 2014/6/15
N2 - Schizophrenia (SZ) is a devastating complex genetic mental condition that is heterogeneous in terms of clinical etiologies, symptoms, and outcomes. Despite decades of postmortem, neuroimaging, pharmacological, and genetic studies of patients, in addition to animal models, much of the biological mechanisms that underlie the pathology of SZ remain unknown. The ability to reprogram adult somatic cells into human induced pluripotent stem cells (hiPSCs) provides a new tool that supplies live human neurons for modeling complex genetic conditions such as SZ. The purpose of this review is to discuss the technical and clinical constraints currently limiting hiPSC-based studies. We posit that reducing the clinical heterogeneity of hiPSC-based studies, by selecting subjects with common clinical manifestations or rare genetic variants, will help our ability to draw meaningful insights from the necessarily small patient cohorts that can be studied at this time.
AB - Schizophrenia (SZ) is a devastating complex genetic mental condition that is heterogeneous in terms of clinical etiologies, symptoms, and outcomes. Despite decades of postmortem, neuroimaging, pharmacological, and genetic studies of patients, in addition to animal models, much of the biological mechanisms that underlie the pathology of SZ remain unknown. The ability to reprogram adult somatic cells into human induced pluripotent stem cells (hiPSCs) provides a new tool that supplies live human neurons for modeling complex genetic conditions such as SZ. The purpose of this review is to discuss the technical and clinical constraints currently limiting hiPSC-based studies. We posit that reducing the clinical heterogeneity of hiPSC-based studies, by selecting subjects with common clinical manifestations or rare genetic variants, will help our ability to draw meaningful insights from the necessarily small patient cohorts that can be studied at this time.
KW - Clinical heterogeneity
KW - genetics
KW - human induced pluripotent stem cells
KW - mouse model
KW - neuronal differentiation
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84901313139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901313139&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2013.10.025
DO - 10.1016/j.biopsych.2013.10.025
M3 - Review article
C2 - 24331955
AN - SCOPUS:84901313139
SN - 0006-3223
VL - 75
SP - 936
EP - 944
JO - Biological psychiatry
JF - Biological psychiatry
IS - 12
ER -